Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates
Nov 26, 2025

Authored by Pravin Anand There are areas of intellectual property law where one can sense, quite literally, the convergence of disciplines that do not

When Art Meets Science in Trademark Law: Reflections on India’s First Smell Mark
Thought Leadership
Nov 25, 2025

First published on Lexology. Authored by Vaishali R Mittal In a landmark moment for Indian intellectual property law, the Trademarks Registry has accepted

Scenting the Future: How India’s First Smell Mark Application Aligns with Global Jurisprudence
Thought Leadership
Nov 21, 2025

We are proud to share that the Trade Marks Registry of India has, for the first time, accepted an olfactory (smell) mark for advertisement — “Floral

A Landmark First for Indian Trademark Law
News & Updates
Nov 15, 2025

APPA president Hari Subramaniam congratulates Pravin Anand for receivng the APPA Enduring Impact Award in Kuala Lumpur. ‘First published on India Business

IP expert Pravin Anand honoured with prestigious APAA award